This guidance will fully update the following:
This guidance will partially update the following:
- Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)
- Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Please note that following on from information provided to NICE by the company in March 2021, the appraisal of Non-bisphosphonates for treating osteoporosis [ID901] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 901
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- School of Health and Related Research, University of Sheffield
Stakeholders
- Companies sponsors
- Amgen (denosumab, romosozumab)
- Consilient Health (raloxifene) not participating
- Daiichi Sankyo (raloxifene)
- Eli Lilly (teriparatide)
- Gedeon Richter (teriparatide)
- Internis Pharmaceuticals (teriparatide)
- Mylan UK (raloxifene) – not participating
- Sandoz (raloxifene) – not participating
- UCB (romosozumab)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- National Osteoporosis Society
- Professional groups
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- United Kingdom Clinical Pharmacy Association
- Comparator companies
- Accord Healthcare (alendronate, ibandronate, zoledronate) not participating
- Actavis UK (alendronate, ibandronate, risedronate, zoledronate) not participating
- Amneal Pharma Europe (zoledronate) not participating
- Aurobindo (alendronate, risedronate) not participating
- Consilient Health (ibandronate) not participating
- Creo Pharma (alendronate) not participating
- Dr Reddy’s Laboratories (zoledronate) not participating
- Hospira UK (zoledronate) not participating
- Internis (alendronate) not participating
- Intrapharm Laboratories (zoledronate) not participating
- Medac (zoledronate) not participating
- Merck Sharp & Dohme (alendronate) not participating
- Mylan UK (alendronate, ibandronate, zoledronate) not participating
- Novartis Pharmaceuticals (zoledronate) not participating
- Ranbaxy (ibandronate, zoledronate) not participating
- Rosemont (alendronate) not participating
- Sandoz (risedronate) not participating
- Seacross Pharmaceuticals (zoledronate) not participating
- Warner Chilcott UK (risedronate) not participating
- Zentiva (alendronate, ibandronate) not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Bone Research Society
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in March 2021, the appraisal of Non-bisphosphonates for treating osteoporosis [ID901] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 02 March 2021 | Suspended. Following the recent cancellation of the committee meeting, NICE does not consider that this appraisal, within the current format, will add value to the existing published guidance. Therefore, NICE has decided to suspend this appraisal from its current work programme.. |
| 31 January 2021 | The Committee discussion scheduled for 7 January 2021 has been cancelled. During the preparation for the Committee meeting, NICE has considered whether this appraisal will add value to the existing published guidance and how best to advise the NHS on the use of romosozumab. |
| 22 September 2020 | In progress. This appraisal was delayed due to COVID-19 but has now been rescheduled. |
| 05 May 2020 | Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available. |
| 02 April 2020 | Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear. |
| 29 January 2019 | All of the drugs in this Technology Appraisal must have received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) before the first Appraisal Committee meeting. This will not have happened before the current scheduled meeting in February, therefore we will reschedule this appraisal and the first Committee meeting will take place on 24 April 2019. |
| 15 January 2019 | Assessment report sent for information |
| 18 May 2018 | Invitation to participate |
| 18 December 2017 - 22 January 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 17 June 2016 | Further details regarding the timings of this MTA will be available in due course. |
| 01 March 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual